Skip to main content

Table 1 Baseline characteristics

From: Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo – a post-hoc analysis of the BACE randomized controlled trial

 

Azithromycin

(N = 147)

Placebo

(N = 154)

Demographics

 Age – years

66 ± 9

67 ± 10

 Female sex – no. (%)

66 (45)

66 (43)

 BMI – kg/m2

24.5 ± 5.9

25.1 ± 6.5

Comorbidity

 Charlson comorbidity index

4 [3–5]

4 [3–5]

Lung disease

 mMRC dyspnea score

4 [2–4]

4 [2–4]

 Pre-bronchodilator FEV1 – L

0.90 [0.69–1.23]

0.95 [0.71–1.36]

 Pre-bronchodilator FEV1 – % pred.

36.0 [26.3–53.8]

38.5 [29.0–52.0]

 Pre-bronchodilator FEV1/FVC – %

40.3 [33.6–48.0]

45.0 [37.0–52.8]

 GOLD stage – no. (%)a

  A

0 (0)

1 (1)

  B

26 (18)

30 (20)

  C

1 (1)

2 (1)

  D

120 (82)

121 (79)

 Current smoker – no. (%)

63 (43)

65 (42)

 Smoking history – pack-years

44 [37–50]

43 [35–50]

 Inhaled therapy for COPD – no. (%)

  LABA

136 (93)

145 (94)

  LAMA

118 (80)

123 (80)

  Inhaled corticosteroids

118 (80)

123 (80)

  SABA

108 (73)

109 (71)

Admission presentation

 GP intervention prior to admission – no. (%)

  Systemic corticosteroids

48 (33)

37 (24)

  Antibiotics

50 (34)

54 (35)

Laboratory

 C-reactive protein (mg/L)

14.2 [3.5–61.4]

21.6 [4.5–59.6]

 Leucocytes (× 109/L)

10.95 [9.00–13.89]

9.90 [8.20–13.70]

 Neutrophils (×109/L)

8.20 [6.00–11.20]

7.70 [5.60–11.20]

 Eosinophils (× 109/L)

0.06 [0.00–0.20]

0.07 [0.00–0.20]

Standardized acute treatment

 Received – no. (%)

134 (91)

141 (92)

 Received antibiotic – no. (%)

145 (99)

152 (99)

 Pathogen susceptible to antibiotic b − no. (%)

136 (94)

144 (95)

  1. Data are presented as either no. (%), mean ± SD or median [Q1-Q3 interquartile range]
  2. Abbreviations: COPD Chronic obstructive pulmonary disease, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, GOLD Global initiative for chronic Obstructive Lung Disease, guideline 2017, GP General practitioner, LABA Long-acting beta-agonist, LAMA Long-acting muscarinic antagonist, mMRC Modified Medical Research Council questionnaire, SABA Short-acting beta-agonist
  3. aGOLD stages are not taking the current hospital admission into consideration. bSusceptibility was determined based on the need for antibiotic upgrade prior to discharge. Change or narrowing of the initial antibiotic based on proven bacterial cultures was considered good clinical practice